Myeloid cells in circulation and tumor microenvironment of breast cancer patients

Cancer Immunology, Immunotherapy

Volumn 66, Issue 6, 2017, Pages 753-764

  Toor, Salman M ^a,b   Syed Khaja, Azharuddin Sajid ^a,b   El Salhat, Haytham ^c,d   Faour, Issam ^c   Kanbar, Jihad ^c   Quadri, Asif A ^c   Albashir, Mohamed ^c   Elkord, Eyad ^a,b,e  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

^c TAWAM HOSPITAL   (United Arab Emirates)

^d Al Noor Hospital   (United Arab Emirates)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Breast cancer; Circulation; Myeloid cells; Myeloid derived suppressor cells; Neutrophils; Tumor microenvironment

Indexed keywords

ARGINASE 1; ARGINASE; ARGINASE I, HUMAN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; BREAST CANCER; BREAST TISSUE; CANCER GRADING; CANCER PATIENT; CELL DIFFERENTIATION; CELL EXPANSION; CELL SUBPOPULATION; CIRCULATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MONOCYTE; MYELOID-DERIVED SUPPRESSOR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; BLOOD; BREAST; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR ESCAPE; TUMOR INVASION; YOUNG ADULT;

ADULT; AGED; ARGINASE; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; MYELOID CELLS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 85014749898     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-1977-z     Document Type: Article

References (43)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. doi:10.3322/caac.21262
2. Weigelt B, Peterse JL, van ‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5(8):591–602. doi:10.1038/nrc1670
3. de la Cruz-Merino L, Barco-Sánchez A, Henao Carrasco F, Nogales Fernández E, Vallejo Benítez A, Brugal Molina J, Martínez Peinado A, Grueso López A, Ruiz Borrego M, Codes Manuel de Villena M, Sánchez-Margalet V, Nieto-García A, Alba Conejo E, Casares Lagar N, Ibáñez Martínez J (2013) New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol 2013:785317. doi:10.1155/2013/785317
4. Toor SM, Elkord E (2015) Myeloid-derived suppressor cells. eLS:1–8. doi:10.1002/9780470015902.a0024245/full
5. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. doi:10.1038/nri2506
6. Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3rd (2013) Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 140(1):13–21. doi:10.1007/s10549-013-2618-7
7. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150. doi:10.1038/ncomms12150
8. Khaled YS, Ammori BJ, Elkord E (2013) Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol 91(8):493–502. doi:10.1038/icb.2013.29
9. Moses K, Brandau S (2016) Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol 28(2):187–196. doi:10.1016/j.smim.2016.03.018
10. Chen J, Deng Q, Pan Y, He B, Ying H, Sun H, Liu X, Wang S (2015) Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. FEBS Open Bio 5:502–507. doi:10.1016/j.fob.2015.05.003
11. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166(1):678–689
12. Brandau S, Moses K, Lang S (2013) The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? Semin Cancer Biol 23(3):171–182. doi:10.1016/j.semcancer.2013.02.007
13. Gantt S, Gervassi A, Jaspan H, Horton H (2014) The role of myeloid-derived suppressor cells in immune ontogeny. Front Immunol 5:387. doi:10.3389/fimmu.2014.00387
14. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, Luckner C, Doschko G, Soler G, Eichmann K, Muller FM, Ho AD, Goerner M, Modolell M (2005) Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 105(6):2549–2556. doi:10.1182/blood-2004-07-2521
15. Di Paola M, Angelini L, Bertolotti A, Colizza S (1974) Host resistance in relation to survival in breast cancer. Br Med J 4(5939):268–270
16. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjanen K (1992) Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28 A(4–5):859–864
17. Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K (2014) The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS ONE 9(12):e115103. doi:10.1371/journal.pone.0115103
18. Chaudhary B, Abd Al Samid M, al-Ramadi BK, Elkord E (2014) Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther 14(7):931–945. doi:10.1517/14712598.2014.900539
19. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6(5):1755–1766
20. Grutzner E, Stirner R, Arenz L, Athanasoulia AP, Schrodl K, Berking C, Bogner JR, Draenert R (2016) Kinetics of human myeloid-derived suppressor cells after blood draw. J Transl Med 14:2. doi:10.1186/s12967-015-0755-y
21. Florcken A, Takvorian A, Singh A, Gerhardt A, Ostendorf BN, Dorken B, Pezzutto A, Westermann J (2015) Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. Immunol Lett 168(2):260–267. doi:10.1016/j.imlet.2015.10.001
22. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P (2009) IL4Ralpha + myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182(10):6562–6568. doi:10.4049/jimmunol.0803831
23. Stanojevic I, Miller K, Kandolf-Sekulovic L, Mijuskovic Z, Zolotarevski L, Jovic M, Gacevic M, Djukic M, Arsenijevic N, Vojvodic D (2016) A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. Int Immunol 28(2):87–97. doi:10.1093/intimm/dxv053
24. Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE (2009) Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol 9(7–8):937–948. doi:10.1016/j.intimp.2009.03.021
25. Toor SM, Khaja ASS, El Salhat H, Bekdache O, Kanbar J, Jaloudi M, Elkord E (2016) Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients. Front Immunol 7:560. doi:10.3389/fimmu.2016.00560
26. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1):49–59. doi:10.1007/s00262-008-0523-4
27. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S (2011) A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118(8):2254–2265. doi:10.1182/blood-2010-12-325753
28. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190(7):3783–3797. doi:10.4049/jimmunol.1201449
29. Bergenfelz C, Larsson AM, von Stedingk K, Gruvberger-Saal S, Aaltonen K, Jansson S, Jernstrom H, Janols H, Wullt M, Bredberg A, Ryden L, Leandersson K (2015) Systemic monocytic-MDSC are generated from monocytes and correlate with disease progression in breast cancer patients. PLoS ONE 10(5):e0127028. doi:10.1371/journal.pone.0127028
30. Mundy-Bosse BL, Thornton LM, Yang HC, Andersen BL, Carson WE (2011) Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol 270(1):80–87. doi:10.1016/j.cellimm.2011.04.003
31. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106 (6):dju124. doi:10.1093/jnci/dju124
32. Ma Y, Shurin GV, Peiyuan Z, Shurin MR (2013) Dendritic cells in the cancer microenvironment. J Cancer 4(1):36–44. doi:10.7150/jca.5046
33. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL (2015) Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol 194(7):2985–2991. doi:10.4049/jimmunol.1403134
34. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3(3):483–490
35. Pinzon-Charry A, Ho CS, Laherty R, Maxwell T, Walker D, Gardiner RA, O’Connor L, Pyke C, Schmidt C, Furnival C, Lopez JA (2005) A population of HLA-DR + immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia 7(12):1112–1122
36. Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, Valerio D, Eremin O (2004) Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 53(6):510–518. doi:10.1007/s00262-003-0485-5
37. Kichler-Lakomy C, Budinsky AC, Wolfram R, Hellan M, Wiltschke C, Brodowicz T, Viernstein H, Zielinski CC (2006) Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. Eur J Med Res 11(1):7–12
38. Bailur JK, Gueckel B, Derhovanessian E, Pawelec G (2015) Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res 17:34. doi:10.1186/s13058-015-0541-z
39. Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56(1):37–47 (quiz 50–1)
40. Ignatiadis M, Sotiriou C (2008) Understanding the molecular basis of histologic grade. Pathobiology 75(2):104–111. doi:10.1159/000123848
41. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, Antonia S, Ochoa JB, Ochoa AC (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64(16):5839–5849. doi:10.1158/0008-5472.CAN-04-0465
42. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59(10):1593–1600. doi:10.1007/s00262-010-0855-8
43. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O’Neill A, Mier J, Ochoa AC (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65(8):3044–3048. doi:10.1158/0008-5472.CAN-04-4505